Phase III Study of Icotinib Treat the Patient With Brain Metastasis EGFR-mutant Non Small Cell Lung Cancer Comparing With Whole Brain Radiotherapy

Guangdong Association of Clinical Trials2 sites in 1 country176 target enrollmentOctober 14, 2012

ConditionsBrain Metastasis Non Small Cell Lung Cancer

InterventionsIcotinib whole brain radiation(WBI)

DrugsIcotinib

Overview

Phase: Phase 3
Intervention: Icotinib
Conditions: Brain Metastasis
Sponsor: Guangdong Association of Clinical Trials
Enrollment: 176
Locations: 2
Primary Endpoint: iPFS
Status: Completed
Last Updated: 9 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

EGFR-TKI is good for the patients with EGFR-mutant non-small cell lung cancer.We design this clinical trail to confirm if the efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor(EGFR-TKI )(ICOTINIB) is better than whole brain irradiation for the patient with EGFR-mutant non-small cell lung cancer.

Detailed Description

no available

Registry

clinicaltrials.gov

Start Date

October 14, 2012

End Date

September 14, 2016

Last Updated

9 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Guangdong Association of Clinical Trials

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Patient who was confirmed stage IV NSCLC with EGFR activating mutation and brain metastases by pathologic histology or cytology.
•Patient who brain metastases was shown in MRI or CT scan. Brain metastases lesions should be more than 3.The diameter among these lesions should be more than 1 centimeter.
•Males or females aged ≥18 years, \< 75 years. Eastern Cooperative Oncology Group(ECOG) performance status 0-
•Life expectancy ≥12 weeks. The therapy of surgery,chemotherapy,radiotherapy that the patients were ever received should be more than 2 weeks ago.The patient had recovered from the treatment.
•Males and females should be contraceptive during the period of the trial until 8 weeks after the last administration of icotinib.
•Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
•Written informed consent provided.

Exclusion Criteria

•Patient was received irradiation of brain. Patient with meningeal metastases were confirmed by MRI or cytology test of cerebrospinal fluid.
•Patient is received the treatment of Phenytoin, carbamazepine, rifampicin, phenobarbital, or St. John's Wort.
•Patient was received EGFR Tyrosine Kinase Inhibitor or EGFR monoclonal antibody.
•Interstitial pneumonia.Pericardial effusion, pleural effusion is uncontrolled .
•Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
•Any significant ophthalmologic abnormality ,especially severe dry eye syndrome ,keratoconjunctivitis sicca,Sjogren syndrome,severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions.
•Lack of physical integrity of the upper gastrointestinal tract, or malabsorption syndrome, or inability to take oral medication, or have active peptic ulcer disease.
•Female subjects should not be pregnant or breast-feeding. Adequate hematological function: Absolute neutrophil count (ANC) ≥1.5 x 109/L, and Platelet count ≥100 x 109/L.
•Adequate renal function: Serum creatinine ≤ 1.5 x ULN, or ≥ 50 ml/min. Adequate liver function :Total bilirubin £ 1.5 x upper limit of normal (ULN) and Alanine Aminotransferase (ALT )and Aspartate Aminotransferase (AST )\< 2.5 x ULN in the absence of liver metastases, or \< 5 x ULN in case of liver metastases.
•The symptoms of increased intracranial pressure are uncontrolled after dehydration and cortisone treatment.